Cardio-oncology & other

The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia

Heart RhythmPublished Retrospective case series

Authors' conclusion

Digoxin monotherapy successfully treated fetal tachycardia in only 32% of cases. Adding flecainide improved response to 93%, although it increased side effects, which could be managed with dose reductions. Maternal digoxin levels were stable throughout pregnancy.

Study context

Population
Pregnant women treated for sustained non-hydropic fetal tachycardia, June 2007 to January 2023
Participants
28 women
Exposure
Digoxin monotherapy, with added flecainide in non-responders
  • Combinationn = 18
Outcome
Correlation between maternal drug exposure, effect and side effects

Main finding

As reported in the abstract

  • Equal starting doses of digoxin gave similar maternal digoxin concentrations regardless of gestational age
  • Maternal digoxin concentrations stable throughout pregnancy, little inter-patient variability
  • Flecainide exposure varied within and between patients
  • Responders vs Non-responders: P = 0.504

Observational data: associations, not effects.

Further findings

OutcomeMonotherapyCombinationP value
Conversion to sinus rhythm32%— not stated in the abstract
Fetus/mother digoxin ratiomedian 0.51 (IQR 0.28–0.76) · n = 3median 0.45 (IQR 0.39–0.64) · n = 9P = 0.864

— not stated in the abstract

Conversion to sinus rhythm — Total conversion rate with added flecainide
93% (26/28)
  • Conversion to sinus rhythm: Monotherapy conversion after median 4.5 days (IQR 3-6.5)

Fetus/mother flecainide ratio

Median fetus/mother flecainide ratio
0.82 (IQR 0.69-1.29)

Safety

Side effects, primarily nausea, led to dose reductions; treatment remained effective

Original publication

The maternal exposure of digoxin and flecainide in relation to the safety and effectiveness in the treatment of non-hydropic fetal tachycardia. Heart Rhythm. Published 22 May 2025. doi:10.1016/j.hrthm.2025.05.039

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.